PT - JOURNAL ARTICLE AU - Israel, Ariel AU - Schäffer, Alejandro A. AU - Merzon, Eugene AU - Green, Ilan AU - Magen, Eli AU - Golan-Cohen, Avivit AU - Vinker, Shlomo AU - Ruppin, Eytan TI - Predicting COVID-19 severity using major risk factors and received vaccines AID - 10.1101/2021.12.31.21268575 DP - 2022 Jan 01 TA - medRxiv PG - 2021.12.31.21268575 4099 - http://medrxiv.org/content/early/2022/01/03/2021.12.31.21268575.short 4100 - http://medrxiv.org/content/early/2022/01/03/2021.12.31.21268575.full AB - Background Vaccines are highly effective in preventing severe disease and death from COVID-19, and new medications that can reduce severity of disease have been approved. However, many countries are facing limited supply of vaccine doses and medications. A model estimating the probabilities for hospitalization and mortality according to individual risk factors and vaccine doses received could help prioritize vaccination and yet scarce medications to maximize lives saved and reduce the burden on hospitalization facilities.Methods Electronic health records from 101,039 individuals infected with SARS-CoV-2, since the beginning of the pandemic and until November 30, 2021 were extracted from a national healthcare organization in Israel. Logistic regression models were built to estimate the risk for subsequent hospitalization and death based on the number of BNT162b2 mRNA vaccine doses received and few major risk factors (age, sex, body mass index, hemoglobin A1C, kidney function, and presence of hypertension, pulmonary disease and malignancy).Results The models built predict the outcome of newly infected individuals with remarkable accuracy: area under the curve was 0.889 for predicting hospitalization, and 0.967 for predicting mortality. Even when a breakthrough infection occurs, having received three vaccination doses significantly reduces the risk of hospitalization by 66% (OR=0.339) and of death by 78% (OR=0.223).Conclusions The models enable rapid identification of individuals at high risk for hospitalization and death when infected. These patients can be prioritized to receive booster vaccination and the yet scarce medications. A calculator based on these models is made publicly available on http://covidest.web.appCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of Shamir Medical Center gave ethical approval for this work (129-2-LEU).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData were obtained from patients' electronic health records and IRB approval restrains its use to researchers inside Leumit Health Services. https://covidest.web.app/calculator.html AUCArea Under the CurveBMIBody mass IndexCOPDchronic obstructive pulmonary diseaseCOVID-19Coronavirus disease of 2019GFRglomerular filtration rateLHSLeumit Health ServicesORodds ratioROCReceiver Operating CharacteristicSARS-CoV-2Severe acute respiratory syndrome coronavirus 2